Zurück
Suzanne Hendrix
Aufstrebend20TetraLogic Pharmaceuticals (United States)
Kennzahlen
- h-Index
- —
- Zitationen
- —
- Publikationen
- —
Zusammensetzung
Erst-/Letztautor
20
Erfahrungs-Indikator aus Bibliometrie und der Evidenzstärke der eigenen Studien — kein Qualitätsurteil über die Person.
Studien bei MedPulse
- 2026-04-01Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease.
- 2026-03-01Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease.
- 2026-02-01Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials.
- 2026-02-01A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease.
- Letztautor:in2025-12-01The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trials.